Clinical Trial Update: Pegcetacoplan Long Term Safety and Efficacy Extension Study [Phase 3]

View source ↗

Summary

Long-term safety and efficacy extension study of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH) is ongoing in Phase 3 and is currently active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• EMPAVELI (pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: PNH | Phase 3 | Status: ACTIVE_NOT_RECRUITING